Vikas Goyal, an experienced investor and business development executive, has transitioned to a leadership role at Pandion Therapeutics, an innovative biotech company developing groundbreaking new treatments for autoimmune disease. With an MBA in Business and a focus on Healthcare Management from the prestigious Wharton School and University of Pennsylvania, respectively, Goyal leverages his deep knowledge of neuroscience, strategy, and corporate development to grow and guide biotech companies. Throughout his accomplished career, Goyal has held board seats at Morphic Therapeutic, Nimbus Therapeutics, Pandion Therapeutics (his current post), Zikani Therapeutics, Spero Therapeutics, and CalciMedica. Additionally, he has worked as Principal at SR One, Manager of Corporate Strategy & Development at Infinity Pharmaceuticals, Senior Associate and Co-Founder at Extera Partners, and Senior Analyst at McKinsey & Company. Goyal also co-chaired TiE Social Entrepreneurs and worked as an intern at SR One and an Associate of PureTech Ventures. As a Neurobiology graduate of Harvard University, Goyal remains deeply committed to fostering innovation and improving human health through biotechnology.